文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛儿科与产科急症

以色列重症监护病房中重症COVID-19肺炎孕妇及产后患者分娩后的结局预测因素与病情进展(OB-COVICU):一项全国性队列研究

Outcome predictors and patient progress following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis in intensive care units in Israel (OB-COVICU): a nationwide cohort study.
PubMed 文献 · Lancet Respir Med · 2023-02-03
一句话结论危重孕妇分娩后母体结局恶化,非危重孕妇分娩后迅速改善;作者建议在病情恶化需机械通气前考虑以母体指征干预性分娩。

该多中心、全国性、前瞻性与回顾性队列研究纳入2020年2月1日至2022年1月31日以色列ICU收治的84例妊娠13周至产后1周的重症COVID-19肺炎孕妇,按分娩状态分为未分娩组(34例)、产后组(4例)、分娩-危重组(32例)和分娩-非危重组(14例)。分娩-危重组和产后组结局更差:分别有26/32(81%)和4/4(100%)需要IPPV,12/32(38%)和3/4(75%)需要ECMO,1/32(3%)和2/4(50%)死亡;分娩-非危重组和未分娩组分别仅6/34(18%)和2/14(14%)需要IPPV,无ECMO或死亡。SpO2、S/F比值、P/F比值、ROX指数、SOFA和PORCH评分均对不良母体结局有高度预测价值(p<0.0001)。分娩-危重组在分娩当日恶化并持续至整个ICU住院期间,恢复更慢(ICU时长,Mantel-Cox p<0.0001),而分娩-非危重组分娩后迅速改善;分娩当日是PORCH评分的显著协变量(p<0.0001),但对SOFA评分不显著(p=0.09)。

要点

  • 分娩-危重组81%(26/32)需IPPV、38%(12/32)需ECMO、3%(1/32)死亡;产后组100%(4/4)需IPPV、75%(3/4)需ECMO、50%(2/4)死亡。
  • 分娩-非危重组仅14%(2/14)需IPPV、未分娩组18%(6/34)需IPPV,两组均无ECMO或死亡。
  • SpO2、S/F比值、P/F比值、ROX指数、SOFA和PORCH评分均高度预测不良母体结局(p<0.0001)。
  • 分娩-危重组分娩当日恶化并持续整个ICU住院期,恢复更慢(ICU时长,Mantel-Cox p<0.0001);分娩-非危重组分娩后迅速改善。
  • 分娩当日是PORCH评分的显著协变量(p<0.0001),对SOFA评分不显著(p=0.09)。

适用人群与场景

  • 以色列全国ICU收治的妊娠13周至产后1周、因重症COVID-19肺炎入院的孕妇和产后患者。
  • 排除ICU入住与重症COVID-19肺炎无关的孕妇。

诊断标准与关键阈值

  • 分组标准:未分娩组(入院时妊娠且ICU期间未分娩)、产后组(分娩后≥1天入ICU)、分娩-危重组(入院时妊娠,分娩时接受IPPV或高危需IPPV)、分娩-非危重组(入院时妊娠,分娩时非危重)。
  • 主要纵向结局为SOFA评分,次要纵向结局为PORCH评分(PEEP、氧合、呼吸支持、胸部X线、血流动力学支持)。

研究设计与关键结果

  • 多中心、全国性、前瞻性与回顾性队列研究,2020年2月1日至2022年1月31日纳入84例:未分娩组34例、产后组4例、分娩-危重组32例、分娩-非危重组14例。
  • 分娩-危重组26/32(81%)需IPPV、12/32(38%)需ECMO、1/32(3%)死亡;产后组4/4(100%)需IPPV、3/4(75%)需ECMO、2/4(50%)死亡。
  • 分娩-非危重组2/14(14%)需IPPV、未分娩组6/34(18%)需IPPV,两组均无ECMO或死亡。
  • SpO2、S/F比值、P/F比值、ROX指数、SOFA和PORCH评分均高度预测不良母体结局(p<0.0001)。
  • 分娩-危重组分娩当日恶化并持续整个ICU住院期,恢复更慢(ICU时长,Mantel-Cox p<0.0001);分娩-非危重组分娩后迅速改善。
  • 分娩当日是PORCH评分的显著协变量(p<0.0001),对SOFA评分不显著(p=0.09)。

证据类型、等级与局限

  • 证据类型:多中心、全国性、前瞻性与回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对于ICU住院期间分娩的患者,危重组分娩后母体结局恶化,而非危重组分娩后改善。
  • 作者建议,应以母体指征在病情恶化需机械通气前考虑干预性分娩。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: A key unresolved controversy in severe COVID-19 pneumonitis in pregnancy is the optimum timing of delivery and whether delivery improves or worsens maternal outcomes. We aimed to assess clinical data on every intensive care unit (ICU) day for pregnant and postpartum women admitted to the ICU with COVID-19, with a particular focus on the days preceding and following delivery.

METHODS: In this multicentre, nationwide, prospective and retrospective cohort study, we evaluated all pregnant women who were admitted to an ICU in Israel with severe COVID-19 pneumonitis from the 13th week of gestation to the 1st week postpartum. We excluded pregnant patients in which the ICU admission was unrelated to severe COVID-19 pneumonitis. We assessed maternal and neonatal outcomes and longitudinal clinical and laboratory ICU data. The primary overall outcome was maternal outcome (worst of the following: no invasive positive pressure ventilation [IPPV], use of IPPV, use of extracorporeal membrane oxygenation [ECMO], or death). The primary longitudinal outcome was Sequential Organ Failure Assessment (SOFA) score, and the secondary longitudinal outcome was the novel PORCH (positive end-expiratory pressure [PEEP], oxygenation, respiratory support, chest x-ray, haemodynamic support) score. Patients were classified into four groups: no-delivery (pregnant at admission and no delivery during the ICU stay), postpartum (ICU admission ≥1 day after delivery), delivery-critical (pregnant at admission and receiving or at high risk of requiring IPPV at the time of delivery), or delivery-non-critical (pregnant at admission and not critically ill at the time of delivery).

FINDINGS: From Feb 1, 2020, to Jan 31, 2022, 84 patients were analysed: 34 patients in the no-delivery group, four in postpartum, 32 in delivery-critical, and 14 in delivery-non-critical. The delivery-critical and postpartum groups had worse outcomes than the other groups: 26 (81%) of 32 patients in the delivery-critical group and four (100%) of four patients in the postpartum group required IPPV; 12 (38%) and three (75%) patients required ECMO, and one (3%) and two (50%) patients died, respectively. The delivery-non-critical and no-delivery groups had far better outcomes than other groups: six (18%) of 34 patients and two (14%) of 14 patients required IPPV, respectively; no patients required ECMO or died. Oxygen saturation (SpO2), SpO2 to fraction of inspired oxygen (FiO2) ratio (S/F ratio), partial pressure of arterial oxygen to FiO2 ratio (P/F ratio), ROX index (S/F ratio divided by respiratory rate), and SOFA and PORCH scores were all highly predictive for adverse maternal outcome (p<0·0001). The delivery-critical group deteriorated on the day of delivery, continued to deteriorate throughout the ICU stay, and took longer to recover (ICU duration, Mantel-Cox p<0·0001), whereas the delivery-non-critical group improved rapidly following delivery. The day of delivery was a significant covariate for PORCH (p<0·0001) but not SOFA (p=0·09) scores.

INTERPRETATION: In patients who underwent delivery during their ICU stay, maternal outcome deteriorated following delivery among those defined as critical compared with non-critical patients, who improved following delivery. Interventional delivery should be considered for maternal indications before patients deteriorate and require mechanical ventilation.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Fatnic E, Blanco NL, Cobiletchi R, et al. Outcome predictors and patient progress following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis in intensive care units in Israel (OB-COVICU): a nationwide cohort study. Lancet Respir Med. 2023. PMID: 36746165. doi:10.1016/S2213-2600(22)00491-X

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。